CERo Therapeutics Holdings, Inc. CERO

SRX Global acquires senior secured debt in CERo Therapeutics Holdings, Inc., a cellular immunotherapy company developing a cancer-fighting molecule for hematologic cancers. Debt acquisition injects financial structure changes that may shift CERo's stability and market perception without guaranteeing operational transformation.

CERo Therapeutics Holdings, Inc. (CERO) securities are delisted from The Nasdaq Stock Market. Delisting from Nasdaq eliminates exchange visibility and liquidity for CERO shares.

CERo Therapeutics reported a clinical update from its CERTAIN-T Phase 1 trial of CER-1236, noting a patient who underwent allogeneic stem cell transplant following treatment. Phase 1 trial progress on CER-1236 indicates treatment enabled transplant and may lift near-term sentiment without altering long-term trajectory.

CERo Therapeutics Holdings, Inc. (CERO) completed the second ascending dose cohort in its Phase 1 clinical trial of CER-1236, advancing the study of the engineered T cell therapy. Phase 1 dose cohort completion signals trial progress and safety tolerance for CER-1236 but remains early-stage with limited broader implications.

CERo Therapeutics Holdings, Inc. issued a shareholder update detailing progress on its CER-T platform, including positive preclinical data for cer01 targeting solid tumors, completion of a $7.5 million registered direct offering, upcoming IND filing in H2 2024, and plans to regain Nasdaq compliance post-reverse split. Pipeline advancements and fresh financing provide moderate boost to clinical timeline and market sentiment amid compliance efforts.

CERo Therapeutics Holdings, Inc. (CERO) announces biotech industry veteran Eric Francois joining its Board of Directors. Adding a biotech veteran to the board bolsters strategic expertise and governance, moderately enhancing competitive positioning and investor sentiment.

CERo Therapeutics Holdings, Inc. announced that it will present late-breaking oral poster session data from the CERTAIN-T trial, showcasing interim results that highlight platelet transfusion independence in patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The presentation of promising interim data from a clinical trial could significantly influence investor sentiment and the company's future trajectory.

CERo Therapeutics Holdings, Inc. provided a clinical update on its Phase 1 trial of CER-1236 for acute myeloid leukemia (AML) in the CertainT-1 study. Key safety data was highlighted, including a notable platelet transfusion-free interval observed in a patient with myelodysplastic syndrome/AML, indicating potential therapeutic benefits of CER-1236 in this patient population. The positive safety data and transfusion-free interval could significantly enhance CERo's competitive positioning and investor sentiment in the oncology market.

CERo Therapeutics Holdings, Inc. provided an update on its Phase 1 clinical trial of CER-1236 for acute myeloid leukemia (AML) in the CertainT-1 study. The trial aims to evaluate the safety and efficacy of CER-1236, a novel therapeutic approach targeting AML. Initial results indicate promising safety profiles and potential efficacy, with further data expected to be released in upcoming months. The company remains committed to advancing its clinical programs and addressing unmet needs in AML treatment. The clinical trial results could significantly influence CERo Therapeutics' future market position and investor sentiment.

CERo Therapeutics Holdings, Inc. (CERO) has announced its trading on the OTCQB market, which is expected to enhance its visibility and accessibility to investors. This move aims to facilitate greater liquidity and broaden the company's shareholder base, aligning with its growth strategy. The transition to the OTCQB is seen as a significant step in advancing the company's market presence and operational goals. Trading on the OTCQB market is expected to moderately influence investor sentiment and liquidity, but its overall effect on the company's trajectory remains limited.

CERo Therapeutics Holdings, Inc. has initiated the second cohort of its Phase 1 clinical trial for CER-1236, a treatment for acute myeloid leukemia (AML). The trial involves patients receiving a significant increase in dosing, which aims to evaluate the safety and efficacy of the drug. This advancement marks a critical step in the development of CER-1236 as a potential therapeutic option for AML patients. The initiation of the second cohort in a Phase 1 clinical trial represents a significant advancement in the development of a potentially transformative treatment for AML.

CERo Therapeutics Holdings, Inc. (CERO) announced that it will present data at the Society for Immunotherapy of Cancer Conference, showcasing its lead compound CER-1236. The data highlights sustained cell expansion and cytokine response, indicating potential advancements in immunotherapy treatments. The presentation of significant data on CER-1236 could influence investor sentiment and the company's competitive positioning in the immunotherapy market.

CERo Therapeutics Holdings, Inc. (CERO) has announced its listing on the OTC Markets, which is expected to enhance its visibility and accessibility to investors. This move aims to facilitate trading of its shares and broaden its investor base, potentially leading to increased liquidity and market interest in the company's therapeutic developments. Listing on OTC Markets may moderately enhance visibility and liquidity, influencing investor sentiment and trading activity.

CERo Therapeutics Holdings, Inc. received a determination from the Nasdaq Hearings Panel regarding its compliance with listing requirements. The panel has granted the company an extension until December 31, 2023, to regain compliance with the minimum bid price requirement. This decision allows CERo to continue its efforts to meet the necessary criteria for maintaining its Nasdaq listing. The extension provides a temporary reprieve that may influence investor sentiment and operational focus but does not fundamentally alter the company's trajectory.

CERo Therapeutics Holdings, Inc. announced the administration of the third dose to a patient in its Phase 1 clinical trial of CER-1236, a treatment for acute myeloid leukemia (AML). This milestone marks a significant step in the trial process, which aims to evaluate the safety and efficacy of CER-1236 in patients with AML. The company continues to advance its clinical development efforts in oncology. The progression of the Phase 1 clinical trial for CER-1236 could significantly impact the company's future performance and investor sentiment.

CERo Therapeutics Holdings, Inc. (CERO) will participate in a panel discussion on stem cell therapy at the Maxim Growth Summit 2025. This event will provide a platform for the company to showcase its advancements and engage with industry leaders and investors. Participation in a prominent industry event may enhance visibility and networking opportunities, potentially influencing future developments.

CERo Therapeutics Holdings, Inc. has completed the first cohort of its Phase 1 clinical trial for CER-1236, a treatment aimed at acute myeloid leukemia (AML). The trial is designed to evaluate the safety and tolerability of CER-1236, with initial results indicating a favorable profile. The company plans to continue advancing the trial to further assess the drug's efficacy and potential as a treatment option for AML patients. Completion of the first cohort in a Phase 1 trial for a potential AML treatment could significantly impact the company's future and market performance.

CERo Therapeutics Holdings, Inc. has advanced its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML) by successfully dosing the third patient in the initial dose cohort. This milestone marks a significant step in the trial process as the company continues to evaluate the safety and efficacy of the treatment. Progress in clinical trials can significantly impact future product development and investor sentiment.

CERo Therapeutics Holdings, Inc. (CERO) has received a Notice of Allowance from the U.S. Patent and Trade Office for the composition of matter and method of use for its cancer treatment, CER-1236. This patent protection is expected to last until 2041, potentially enhancing the company's competitive position in the oncology market. The patent allowance is likely to significantly impact CERo's future by securing intellectual property rights for a promising cancer treatment.

CERo Therapeutics Holdings, Inc. announced a dose intensification in its Phase 1 study of CER-1236, a treatment for Acute Myeloid Leukemia (AML). This decision follows positive preliminary results, indicating the potential for enhanced efficacy in patients. The study aims to evaluate the safety and tolerability of the drug, with the intensified dosing expected to provide further insights into its therapeutic benefits. The company remains focused on advancing its clinical programs to address unmet medical needs in AML. The dose intensification in a clinical trial could significantly impact the drug's efficacy and the company's future market position in oncology.

CERo Therapeutics Holdings, Inc. has received FDA Fast Track Designation for its investigational drug CER-1236, aimed at treating Acute Myeloid Leukemia (AML). This designation is intended to expedite the development and review process for drugs that treat serious conditions and fill an unmet medical need. The company aims to advance CER-1236 through clinical trials more swiftly, potentially improving treatment options for AML patients. FDA Fast Track Designation can significantly accelerate the development and market entry of CER-1236, impacting the company's future performance and investor sentiment.

CERo Therapeutics Holdings, Inc. has successfully dosed its second patient with CER-1236, a treatment aimed at acute myeloid leukemia (AML). This milestone marks a significant step in the company's clinical development program for CER-1236, which is designed to target and treat AML more effectively. The ongoing trials are expected to provide further insights into the safety and efficacy of the treatment, potentially paving the way for future advancements in AML therapies. Dosing a second patient in a clinical trial for a novel AML treatment indicates significant progress in product development and could enhance investor confidence.

Invivoscribe has expanded its flow cytometry services to support the development and regulatory readiness of CAR-T immunotherapy. This expansion coincides with the initiation of CERo Therapeutics Holdings, Inc.'s Phase 1 clinical trial, which aims to enhance the efficiency and effectiveness of CAR-T therapies. The initiation of a Phase 1 clinical trial represents a significant strategic move that could enhance CERo's market position and investor sentiment.

CERo Therapeutics Holdings, Inc. announced that the first patient in its Phase 1 trial of CER-1236 has completed the dose-limiting toxicity observation period with no reported dose-limiting toxicities (DLTs). This milestone is a positive indicator for the safety profile of CER-1236 as the trial progresses. The completion of the observation period without DLTs suggests a moderately positive influence on the company's clinical development and investor sentiment.

CERo Therapeutics Holdings, Inc. announced that the FDA has granted Orphan Drug Designation for its lead drug candidate, CER-1236, aimed at treating acute myeloid leukemia (AML). CER-1236 utilizes engineered T cell therapeutics with phagocytic mechanisms and is currently in Phase 1 clinical trials to assess safety and efficacy in various AML patient groups. The designation provides CERo with several incentives, including FDA assistance in trial design and potential marketing exclusivity. CEO Chris Ehrlich emphasized the significance of this designation for advancing AML treatments. The FDA's Orphan Drug Designation for CER-1236 is a significant regulatory milestone that could enhance CERo's market position and investor sentiment.

CERo Therapeutics Holdings, Inc. announced a 1-for-20 reverse stock split aimed at increasing the per-share price of its common stock. The split is intended to help the company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq. The reverse split will take effect on a specified date, and shareholders will receive one new share for every twenty shares they currently own. The reverse stock split is a strategic move to maintain Nasdaq listing compliance, which may influence market sentiment and stock performance.

CERo Therapeutics Holdings, Inc. announced a reverse stock split aimed at increasing the per-share price of its common stock. The split will be executed at a ratio of 1-for-15, effective on a specified date. This move is intended to help the company meet the minimum bid price requirement for continued listing on the Nasdaq stock exchange. The company believes this action will enhance its marketability and attract potential investors. The reverse stock split is a strategic move to maintain Nasdaq listing requirements, which may influence investor sentiment and market perception.

CERo Therapeutics Holdings, Inc. has issued additional shares of its Series D Preferred Stock to institutional investors, raising approximately $750,000 with the potential for up to $2.25 million more. This financing follows a previous agreement from April 2025, totaling up to $8 million. The funds will support clinical trials for CER-1236, a CAR-T therapeutic candidate targeting TIM 4L, and facilitate site activations for FDA IND allowances in liquid and solid tumors. CEO Chris Ehrlich highlighted the company's progress in clinical development. The financing and clinical advancements are likely to significantly impact CERo's future performance and investor sentiment.

CERo Therapeutics Holdings, Inc. (CERO) announced the granting of two U.S. patents and the allowance of a European patent application, enhancing its intellectual property portfolio. U.S. Patent No. 12,291,557 covers design aspects of CER-1236, a chimeric TIM4 receptor. The allowed European Patent Application No. 1882166.7 expands protection for additional design aspects of CER-1236. Additionally, U.S. Patent No. 12,303,551 provides coverage for combination cellular immunotherapy compositions involving CER-1236, which could enhance cancer treatment strategies. CERo now holds 9 patent families with protection extending to 2042 in the U.S. The granted patents and allowed applications significantly strengthen CERo's competitive position and potential for innovative cancer therapies.

CERo Therapeutics Holdings, Inc. announced the granting of two U.S. patents and the allowance of a European patent application, enhancing its intellectual property portfolio related to its lead compound CER-1236. The U.S. Patent No. 12,291,557 covers design aspects of a chimeric TIM4 receptor, while U.S. Patent No. 12,303,551 provides coverage for combination cellular immunotherapy compositions. The European patent application expands protection for additional design aspects of CER-1236. With these developments, CERo's portfolio now includes 18 total issued patents and allowed applications internationally, supporting its innovative immunotherapy approach for cancer treatment. The granted patents significantly enhance CERo's competitive position and potential for future product development in cancer therapy.